Augtyro
Augtyro Approved for Adult and Pediatric Patients With NTRK Gene Fusion-Positive Solid Tumors
The FDA has granted accelerated approval to repotrectinib (Augtyro, Bristol Myers Squibb) for adult and pediatric ...
JUNE 14, 2024
FDA Approves Augtyro for ROS1-Positive Non-Small Cell Lung Cancer
The FDA approved repotrectinib (Augtyro, Bristol Myers Squibb) for locally advanced or metastatic ROS1-positive ...
NOVEMBER 16, 2023
Load more